Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study

Bulletin Express

04/09

Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.

The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.

The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1108148998"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108148998\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108148998?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108148998","market":"hk","top_or_hot":-1,"title":"Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study","media":"Bulletin Express","content":"<p>Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.</p>\n<p>The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.</p>\n<p>The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-04-09 18:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.</p>\n<p>The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.</p>\n<p>The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉醫療-B","start_time":0,"source_url":"","article_id":"1108148998","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108148998","pubTimestamp":1775731623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"沛嘉医疗在GeminiOne TEER早期可行性研究中完成首例美国患者植入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.\nThe company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.\nThe announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}